biostudies-literatureUnknown114(1)De Novellis DIsatuximab, a novel anti-CD38 monoclonal antibody, is approved in combination with carfilzomib and dexamethasone (Isa-Kd) in relapsed/refractory multiple myeloma (RRMM) patients. Because of its recent introduction, real-world efficacy and safety are poorly reported. In this Italian multicenter real-life observational retrospective study, efficacy and safety of the Isa-Kd regimen were evaluated in a cohort of 103 RRMM patients. Overall response rate (ORR) was 85%, with stringent (sCR) or complete response (CR) in 18% of cases and very good partial response (VGPR) in 39%. Median PFS and OS were not reached within the study period, while 1-year PFS and OS were 72% and 77%, respectively. Hematological toxicities were observed in 42% of subjects, and cardiac toxicities occurred in 24% of cases.European journal of haematology105-114https://www.ebi.ac.uk/biostudies/studies/S-EPMC11613624biostudies-literatureClinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.PMC11613624Risitano AMTosi PMorini DMasucci CFalcone APLeone ARocco SSicari MCarella AMMarano LGigliotta ELazzaro ASalvatore FPane FBotta CMarcacci GFontana RCalifano CIdato AMorello LGiudice VSvanera GCarlisi MRotondo FPalmieri SAccardi FMorelli EArcamone MFrigeri FRoccotelli DUrciuoli EBianco RFanelli FCetani GVincelli DDelle Cave GPorrazzo MDella Pepa RDi Perna MEsposito DDe Novellis DTrastulli FBarone MLDerudas DRizzo MAnnunziata MSelleri CRascato MGSerio BfalseClinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.Isatuximab, a novel anti-CD38 monoclonal antibody, is approved in combination with carfilzomib and dexamethasone (Isa-Kd) in relapsed/refractory multiple myeloma (RRMM) patients. Because of its recent introduction, real-world efficacy and safety are poorly reported. In this Italian multicenter real-life observational retrospective study, efficacy and safety of the Isa-Kd regimen were evaluated in a cohort of 103 RRMM patients. Overall response rate (ORR) was 85%, with stringent (sCR) or complete response (CR) in 18% of cases and very good partial response (VGPR) in 39%. Median PFS and OS were not reached within the study period, while 1-year PFS and OS were 72% and 77%, respectively. Hematological toxicities were observed in 42% of subjects, and cardiac toxicities occurred in 24% of cases.2025-01-01T00:00:00Z2025 Jan2026-06-01T15:27:41.376Z2025-04-04T02:34:03.571ZS-EPMC116136243937030310.1111/ejh.14314